Brief: Celltrion Submits Plan For Phase 3 Clinical Trials For Darzalex Biosimilar Ct-P44 To South Korean Regulator
20/03/2025 04:23
Celltrion Inc 068270.KS: CELLTRION: SUBMITS PLAN FOR PHASE 3 CLINICAL TRIALS FOR DARZALEX BIOSIMILAR CT-P44 TO SOUTH KOREAN REGULATOR Source text: [ID:] Further company coverage: 068270.KS
Recent news on Celltrion
See all newsBrief: Celltrion Inc To Acquire 100 Billion Won Worth Of Own Shares
Brief: Celltrion Q1 Operating. Profit 322 Billion Won, Up 115% Y/Y
Brief: Celltrion To Cancel 100 Billion Won Treasury Shares
Brief: Celltrion Plans Phase 3 Clinical Trials For Keytruda Biosimilar With 220 Patients
Brief: Celltrion To Buy 100 Billion Won Of Own Shares